Intelligence Β· Patent portfolio
S.L Patents
Full USPTO pharma patent portfolio for S.L β grant dates, expiration, and drug cross-links.
- Patents
- 179
- Expiring β€24m
- 16
Quick answer
S.L has 179 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 16 expire within 24 months β use filters for patent-cliff planning.
-
US 12311017
Identification of immunologically protective neo-epitopes for the treatment of cancers
granted -
US 12251378
Long-acting local anesthetic formulation
granted -
US 12202822
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 12156879
Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
granted -
US 12060555
MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis
granted -
US 12029787
Method for generating recombinant poxviruses
granted -
US 12018255
Compositions and methods for treating disorders of genomic imprinting
granted -
US 11952419
Reagents and methods for treating cancer and autoimmune disease
granted -
US 11866488
Compositions comprising an anti-metallothionein antibody and a pancreatic cell targeting moiety
granted -
US 11866491
Antibody for binding to interleukin 4 receptor
granted -
US 11833254
Discoidal nano universal platform for efficient delivery of PNAs
granted -
US 11786479
Nucleic acid nanocapsules for drug delivery and targeted gene knockdown
granted -
US 11512078
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 11497197
Methods for enhancing poultry growth and performance
granted -
US 11479617
Chelator-functionalized glycosaminoglycans
granted -
US 11459381
Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
granted -
US 11390613
Azole analogues and methods of use thereof
granted -
US 11364309
Neuronal enhancers
granted -
US 11338026
Identification of immunologically protective neo-epitopes for the treatment of cancers
granted -
US 11173173
Methods for treating chemoresistant cancer-initiating cells
granted -
US 11103523
Self-assembled brush block copolymer-nanoparticles for drug delivery
granted -
US 11078264
Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
granted -
US 11020459
Factor VIII formulations
granted -
US 11008378
Compositions and methods for immunomodulation in an organism
granted -
US 10870625
Zwitterionic propargyl-linked antifolates useful for treating bacterial infections
granted -
US 10842826
Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
granted -
US 10814006
Fluorescent prodrugs
granted -
US 10780058
Nucleic acid nanocapsules for drug delivery and targeted gene knockdown
granted -
US 10774141
Antibody for binding to interleukin 4 receptor
granted -
US 10632072
Systems and methods for continuous manufacturing of liposomal drug formulations
granted -
US 10537594
Targeted transplantation of mitochondria to hepatocytes
granted -
US 10501801
Identification of tumor-protective epitopes for the treatment of cancers
granted -
US 10464993
Compositions and methods for immunomodulation in an organism
granted -
US 10457726
Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
granted -
US 10344040
Pyridone and aza-pyridone compounds and methods of use
granted -
US 10280158
Immune adjustment compound, use thereof and pharmaceutical composition comprising same
granted -
US 10266539
Polymorph of Syk inhibitors
granted -
US 10226488
Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
granted -
US 10092583
Imidazopyridines Syk inhibitors
granted -
US 10093684
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
granted -
US 10053469
Pyridone and aza-pyridone compounds and methods of use
granted -
US 9975983
Bio-reducible self-assembled liquid crystalline block copolymer for drug delivery
granted -
US 9969790
Compositions and methods for immunomodulation in an organism
granted -
US 9949932
Formulation of syk inhibitors
granted -
US 9932387
Compositions and methods for immunomodulation in an organism
granted -
US 9918939
Formulation of Syk inhibitors
granted -
US 9839636
Itraconazole analogues and methods of use thereof
granted -
US 9796718
6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine
granted
Frequently asked questions
How many patents does S.L have?
179 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do S.L patents expire?
16 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory